Frontlight ResearchEarly access
Taking people in SpainPhase 4
Sumatriptan and Rimegepant Compared in People With Episodic Migraine
Compares sumatriptan and rimegepant during nitroglycerin-induced headache in adults with migraine.
Key facts
- Who runs it
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- Where
- Barcelona, SpainSee the site
- Trial code
- Registry title
- Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study).
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 24 people, planned
- Started
- 5 Mar 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 5 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with episodic migraine who have fewer than 10 headache days a month and do not take preventive migraine treatment.
- Age
- Adults between 18 and 60 years old (the registry also lists 18 to 64 years).
- Sex
- All sexes can join.
- Disease stage
- Migraine with or without aura, diagnosed by the International Classification of Headache Disorders 3rd edition, with fewer than 10 headache days per month.
- Earlier treatment
- People cannot have taken preventive migraine treatment or drugs acting on the central nervous system. People with poor tolerance of triptans or gepants cannot join.
Main reasons for not taking part
- Cannot take nitroglycerin
- Pregnant women, or women who can have children and do not use an acceptable birth control method
- Past severe or refractory migraine attacks that did not respond to triptans, gepants or NSAIDs
- Unstable ischemic heart disease, cerebrovascular disease or peripheral vascular disease
- Significant liver disease or other relevant medical or psychiatric disease
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Adults between 18 and 60 years old
- Diagnosis of migraine, with or without aura, according to the The International Classification of Headache Disorders 3rd edition
- According to the calendar, frequency of cefalea < 10 days/month
- Signature of the Inform Consent Form
Who cannot take part
- History of poor tolerance or prior hypersensitivity reaction to triptans or gepants
- History of severe or refractory migraine attacks unresponsive to treatment with triptans, gepants, or NSAIDs
- Preventive treatment for migraines (includes antidepressants, beta-blockers, lisinopril or candesartan, topiramate, valproic acid, botulinum toxin, or CGRP-targeted therapies)
- Tretament with drugs acting on the central nervous system
- Relevant medical or psychiatric diseases
- History of unstable ischemic heart disease, cerebrovascular disease, peripheral vasculopathy
- History of significant hepatic disease
- Contraindication to nitroglycerin
- Child-bearing women that not use one acceptable method of birth contro
- Pregnant women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
About the trial
What the trial wants to find out
- Temporal Evolution of Biochemical Marker Levels in Blood During NTG-Induced Migraine Attacks and After Treatment with Sumatriptan and Rimegepant - Correlation of Biochemical Marker Profiles with Acute Treatment Response to Sumatriptan and Rimegepant During NTG-Induced Migraine Attacks.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Randomized Cross-Over Experimental Trial of Treatment with Sumatriptan vs. Rimegepant During Nitroglycerin (NTG)-Induced Headache in Patients with Episodic Migraine for the Determination of Molecular and Clinical Biomarkers (MAMBO II Study).
- Plain-language title
- Sumatriptan and Rimegepant Compared in People With Episodic MigraineGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2024-519770-38-00, who can take part
- Record updated
- 5 June 2026